North America Leads Global Influenza Diagnostics Industry Expansion

According to the latest market research study published by P&S Intelligence, the global influenza diagnostics market was valued at USD 946.9 million in 2023 and is anticipated to grow at a CAGR of 7.9%, reaching USD 1,603.1 million by 2030. The primary drivers of this growth include increasing rates of chronic diseases exacerbated by influenza, the aging population, and enhanced government efforts to track and manage flu outbreaks. The continuous advancement of diagnostic technologies and the development of more effective tools to detect and manage influenza have significantly contributed to market expansion. Governments are funding research for better diagnostic solutions, such as the NIH’s support for flu-related initiatives, which has further boosted market dynamics.

Technological innovations, particularly in molecular diagnostics and point-of-care testing, are shaping the future of the influenza diagnostics market. The rising development of combination tests for influenza and COVID-19 is also expected to drive market growth. With an increasing number of diagnostic tests becoming available for smaller clinics and research institutions, these innovations are making influenza diagnostics more accessible and efficient.

Key Insights

Product Segmentation

The test kits and reagents segment led the market in 2023, capturing 60% of the total market share. This dominance is driven by the widespread availability of test kits and their affordability, which make them popular among healthcare providers and consumers alike. Point-of-care testing kits are becoming especially significant as they allow for quick, at-home diagnosis, eliminating the need for in-person visits.

Instruments Segment

The instruments segment is expected to grow at the highest CAGR of 8.3% from 2024 to 2030, fueled by increased healthcare spending globally. This growth reflects the rising number of hospitals and diagnostic centers, which are investing in advanced diagnostic instruments for more reliable influenza detection.

Test Types

Traditional diagnostic tests hold a significant market share, with rapid influenza diagnostic tests (RIDTs) playing a pivotal role due to their ease of use and rapid results. However, molecular diagnostic tests, such as RT-PCR, are also experiencing high demand due to their greater accuracy in detecting influenza, particularly influenza B, and for determining the severity of infections.

Geographical Insights

North America accounted for the largest share, 65%, of the global market in 2023. The region’s strong healthcare infrastructure, high prevalence of influenza, and extensive government health programs are driving market expansion. This region is also leading in the adoption of advanced diagnostic tools and technologies.

Technological Advancements

Rapid advancements in diagnostic technologies, such as the development of combination tests for influenza and COVID-19, are transforming the market. These innovations not only improve diagnostic speed but also allow for simultaneous screening of multiple infections, enhancing the efficiency of flu monitoring and management in clinical settings.

Competitive Landscape

Major companies in the influenza diagnostics market are focusing on the development of advanced and more reliable diagnostic tools. For example, Roche has launched a combination test for COVID-19 and influenza, addressing the increased demand for multi-disease diagnostic solutions. Moreover, the rising trend of point-of-care (POC) testing, including at-home test kits, is expected to increase competition in the market.

Opportunities

With the increasing prevalence of influenza and the growing demand for early diagnosis and treatment, opportunities exist for the development of faster, more accurate, and cost-effective diagnostic tools. Research funding and government programs, such as the NIH’s funding for influenza research, are expected to further fuel these opportunities, making the market an attractive space for new entrants and existing players.

Read More

Pharmaceutical Sterility Testing - Industry Development and Forecast Report, 2030

In 2023, the global pharmaceutical sterility testing market revenue is estimated to rise to USD 1,769.0 million and grow at an 11.5% compound annual growth rate between 2024 and 2030, reaching a value of USD 3,763.0 million by 2030.

This development of the market can be credited to the enlargement of pharmaceutical and biotechnological companies, the surge in their R&D activities, the rise in the occurrence of diseases, and significant government investments in the healthcare industry.

The frequency of hematological malignancies is on the surge. As per The Leukemia & Lymphoma Society, every 3 minutes, an individual is diagnosed with lymphoma, myeloma, and leukemia in the U.S. Biopharmaceuticals, like gene, immune, and cell therapies, are quickly being accepted as an alternate treatment for hematological cancers. This is mainly because these therapeutics show high potency and efficiency against these diseases.

In 2023, the North American region dominated the market, with a revenue share of 55%. This can be credited to the existence of key pharmaceutical and bio-pharmaceutical companies, growing R&D activities in the biotechnology and pharmaceutical industries, an increasing number of product introductions, the high occurrence of chronic illnesses, and helpful government rules for the setup of research and development facilities in the continent. 

Furthermore, the existence of strong healthcare guidelines, strict drug approval needs, increasing public awareness of drug safety, improving acceptance of cutting-edge tech, and the launch of gene and cell therapies for the cure of various hematologic malignancies are causing the enlargement of the regional industry.

Read More

How are Medical Devices and IVD Medical Devices Different from Each Other?

Medical devices and IVD medical devices have come in handy for saving the lives of the people with the help of state-of-the-art healthcare solutions for the finding out, treating, monitoring, predicting, or reducing the ill effects of a disease. 

Difference Between Medical Device and IVD medical Device

If we are to talk about the major difference between a medical device and an IVD medical device is that the latter are tests put to use on biological samples like, tissues, urine or blood to regulate the status of the health of a person.

IVD medical devices do not come in contact with a person.  These fulfil their role based on info that is offered by them and not on their action on the patient.  Although IVD devices do not bring about direct harm, they might pose risks if their usage brings about wrong diagnoses and puts people at increased risk of making irreversible medical decisions based on imprecise test results.

So, it is significant that IVD medical devices prove safety and efficiency through diagnostic and clinical validation.

To be precise, the IVD medical device is any medical device which is a reagent, instrument, apparatus, equipment, software or system, whether it is used alone or in combination with some other device, to be used for the inspection of specimens, as well as blood and tissue donations, derived from the human body.

There are more than 40,000 different IVD products available offering info to both patients and doctors regarding various medical conditions. These include tests for pregnancy, which are done on your own and tests for diabetics, to sophisticated diagnoses done in labs.

There are also some of the other IVD devices like HIV tests, human genetic testing devices, those used for blood grouping, or COVID tests.

IVD Medical Devices Make an Integral Part of Modern Healthcare

IVDs have become an integral part of modern healthcare since there are a lot of decisions, which are influenced by the results of the tests, done with the help of these devices. 

With allowing earlier and targeted treatments, IVDs reduce the duration of hospital stays for the people and also side-effects, which result in much improved health condition of the people, reduced costs of healthcare.

Coming to a Concrete Conclusion

In conclusion, it can be said that IVD medical devices guide users to the right healthcare professional and can reduce the time taken to get the final diagnosis, which is every so often related with expensive diagnostic procedures.  So, doctors can make faster and precise diagnostic decisions and consequently advance the path of the treatment of the patient and decrease the cost incurred in treatment.

There are increasing cases of blood disorders all over the world, and for the diagnosis of the same, there is a need for IVD tests to be performed. Due to this, the demand for IVD tests will continue to increase in the future also, and will reach a value of USD 127.4 billion, in another seven years from now.

Read More

Blood Screening Market Is Driven by Strict Regulations Concerning Blood Contamination

According to a statement by a market research institution, P&S Intelligence, the blood screening industry is experiencing significant growth, and it will continue to grow further in the years to come.

To learn more about this report: https://bit.ly/3NitxE3

The key reasons driving the growth of this industry are the strict rules concerning contaminated blood, mounting healthcare expenses, advancement in the technology of blood screening, and high incidence of infectious, respiratory, and chronic illnesses.

Based on product type, the reagents and kits category accounted for the largest share in the past few years. This is because of the easy accessibility of numerous reagents and the necessity for these products in the first stage of the blood screening process.

In recent years, the North American industry contributed the largest share, owing to the high prevalence of respiratory and infectious illnesses in this region. The increasing government support concerning the adoption of advanced screening products is a key factor driving the regional industry growth.

The APAC blood screening industry is expected to observe the fastest growth in the years to come.

A major trend observed in the blood screening industry is the rising number of mergers and collaborations between main industry players.

In the past few years, the blood screening industry player has been involved in numerous new and advanced product launches, to gain a competitive edge.

It is because of the rising incidence of chronic illnesses, rules to ensure safety regarding blood contamination, technological advancements in screening technology, and the increasing number of blood donors, the blood screening industry will continue to grow in the years to come.

Read More

Hospital Acquired Infection Control Industry Will Grow Fastest in Asia-Pacific

The hospital-acquired infection control market will touch USD 34,909.7 million by 2030, driven at a rate of 1.6%. The industry advance will be powered by the growing count of surgical procedures, increasing consciousness of environmental and personal hygiene, and rising chronic disease prevalence.

To learn more about this report: https://bit.ly/3WKNhmN

All patients who are hospitalized are vulnerable to contracting a nosocomial infection. Young children, the aged, and people with a weak immune system are more vulnerable to HAIs than others.

Thus, disinfection is a popular procedure, with an over 68% market share in the past, with hospitals trying to lower the rates of HAIs. HAI symptoms can appear in two–three days after a patient's hospital admission and continue for up to 10 days post discharge. For preventing these infections, the acceptance of disinfection is on the rise. Some widely used disinfectants for preventing the spread of nosocomial infections are glutaraldehyde, formaldehyde, and hydrogen peroxide.

Recently, a drastic rise in the occurrence of neurological ailments, traumatic wounds, and CVDs and the introduction of cutting-edge surgical technologies, to manage and treat them, have been observed. As a result of these events, HAI control product demand is witnessing growth. For example, people suffering from neurological infections or accidents every year number nearly 20 million, approximately 14 million of whom need surgery.

Therefore, north America dominated the hospital-acquired infection control market, with a 35% revenue share, as stated by P&S Intelligence. This is because of the increase in the elderly population, the surge in the incidence of chronic diseases and HAIs, and the existence of prominent market players. For example, in the U.S., the population of people more than 65 years is nearly 45 million, and this number will reach more than 80 million by 2050.

Furthermore, the incidence of HAIs in the continent is extremely high. At hospitals in the U.S., the incidence of HAIs is above 1.5 million, and 100,000 people die of them each year.

APAC will grow the fastest in the years to come. In developing and underdeveloped nations, the requirement for HAI control solutions is on the rise on account of the increasing count of patients and economic development.

Moreover, the acceptance of cutting-edge medical equipment is snowballing with the augmentation in governments’ spending on healthcare sector, which is primarily being seen in a rise in the count of community, primary-care, secondary-care, and tertiary-care medical centers. Further, these nations lack the resources and awareness required to control HAIs, which makes the region a key opportunity area for market players.

It is because of the increasing number of surgical procedures that the demand for hospital-acquired infection control will increase even further in the years to come.

Read More

The Future of Endodontic Devices

As per a market research report by P&S Intelligence, the endodontic devices industry was USD 1,492.0 million in 2021, and it will power at a compound annual growth rate of 4.8% in the years to come, to reach USD 2,283.4 million by 2030.

To learn more about this report: https://bit.ly/3Mf892t

Instruments leads the industry, and it will generate a revenue of USD 1,206.7 million in 2030, as a result of the expansions in delivery systems, which have provided multiple benefits to dentists, for example ease of treatment and maneuvering of handpieces throughout surgeries. 

These delivery systems are now obtainable as over-the-head, side, rear, and over the-patient alternatives. Over-the-patient systems license free movement of patient’s head throughout operations, therefore allowing their easy steering for an enhanced field vision.

North America endodontic devices market dominated the scene, and will generate a revenue of USD 898 million in 2030, at a rate of 4.6% in the years to come. 

Some key factors powering this growth are the increasing population, snowballing investments in dentistry research and developments, rising preference for root canal treatments over implants, and propagation of experts and dental clinics.

It is because of the rise in dental tourism, the demand for endodontic devices will be considerably on the rise in the years to come.

Read More

Demand for Autoimmune Disease Diagnostic Products Remains High in North America

The global autoimmune disease diagnostics market attained a valuation of $4,086.2 million in 2019 and is predicted to exhibit a CAGR of 8.5% between 2020 and 2030. Furthermore, the market is predicted to generate a revenue of $10,012.9 million in 2030. The key factors fueling the advancement of the market are the increasing discoveries of novel biomarkers, rising strategic development activities and initiatives being taken by the key market players, and the growing incidence of autoimmune diseases across the world.

Get the sample pages of this report: https://bit.ly/3EOVmyW

As per the findings of the John Hopkin’s University, nearly 3% of the population or around 10 million people in the U.S. are affected by autoimmune diseases every year. Moreover, according to the reports of the Myasthenia Gravis Foundation of America in June 2015, in the U.S., out of every 100,000 people, 14–20 individuals suffered from myasthenia in 2014, The disease affected nearly 36,000–60,000 people in the country.

Besides the aforementioned factor, the growing public awareness about autoimmune diseases is also propelling the market growth all over the globe. Numerous conferences are predicted to be held in the second half of 2020 and throughout the next year for raising public awareness about autoimmune diseases and the various advancements being made in the treatment of these diseases. The 12th International Congress on Autoimmunity is set to be held from November 28, 2020 to December 1, 2020, in Athens, Greece.

Additionally, the increasing number of initiatives being taken by several private and public organizations for raising the public awareness of autoimmune diseases is causing a huge upswing in the market advancement. Depending on product, the autoimmune disease diagnostics market is divided into instruments, and consumables and assay kits. Between these, the consumables and assay kits category will dominate the market in the forthcoming years. This will be because of the increasing incidence of autoimmune diseases across the world.

Furthermore, the growing requirement for various tests, including rheumatoid factor (RF) & anti-cyclic citrullinated peptide (CCP) antibody, antinuclear antibody (ANA) immunofluorescence assay (IFA), and enzyme-linked immunosorbent assay (ELISA) will boost the expansion of the market throughout the globe in the coming years. When application is taken into consideration, the autoimmune disease diagnostics market is categorized into multiple sclerosis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma, sarcoidosis, myasthenia gravis, and Sjögren’s syndrome.

Geographically, the autoimmune disease diagnostics market is predicted to exhibit the fastest growth in the Asia-Pacific region in the upcoming years. This would be a result of the existence of prominent market players, the availability of cost-effective diagnostic tests and affordable labor, soaring geriatric population, and the rising number of initiatives being taken by several private and public organizations for raising the public awareness about autoimmune diseases in the region.

Hence, it can be said with surety that the market would exhibit huge expansion all over the world in the coming years, primarily because of the growing incidence of autoimmune diseases, the surging geriatric population, and the increasing public awareness about autoimmune diseases in several countries around the world. 

Read More

Epigenetics Industry To Propel At a Mammoth Growth rate of over 17%

In 2021, the size of the epigenetics market was about $1,564 million, and it is will advance at a mammoth growth rate of over 17% in the years to come, to reach a value of around $6,461 million by 2030.  The factors affecting the growth of the industry include the fast development of simple, lucrative and advanced epigenetically kits and increasing acceptance of precision medicine all over the world.

The kits, assays, and reagents had over 60% share in the recent past. This is generally credited to the rapid expansion of simple, affordable, and innovative epigenetics kits and reagents. Also, there has been a surge in product launches, consciousness of non-oncological ailments and epigenetics, and prominence on the acceptance of precision medicine tactics recently.

To learn more about this report: https://bit.ly/3HYxBpd

Oncology made a significant amount of revenue in 2021 for the reason of the momentous increase in the number of cancer cases every year. This will increase as the worldwide occurrence of cancer and related fatalities increase. Also, the industry will grow due to the product launches and the likely commercialization of the products by now thought about for the future.

Pharmaceutical & biotechnology corporations had the largest demand. This is because of the research and development actions on microorganism-derived drug resistance, molecular aspects of cancer, oncology, and drug discovery for non-oncology purposes. Also, the growth would be powered by the growing research in genetics, with a strong prominence on modified treatment.

In 2021, North America had the highest revenue. The dominance is because of the existence of innovative healthcare infra and well-known companies following research and development in epigenetics, increasing count of cancer patients, and snowballing acceptance of products based on cutting-edge molecular know-hows by pharmacological and biotechnological corporations. Also, a great importance on epigenetics biomarker research like on DNA, histones, and non-coding RNA, will support the regional market growth.

Europe followed North America epigenetics market with over 25%, in the recent past because of the surge in the incidence of chronic diseases that require detailed diagnosis. More than a few European countries like France, Germany, the U.K., Spain, and Italy are working tirelessly for improving research initiatives. Further, because of the high backing, the European region has at all times been at the frontrunner of research and diagnostics globally.

APAC will witness the highest growth rate of over 15%, in the years to come. The growing healthcare consciousness, a stable economy leading to a firming emphasis on research, and extensive acceptance of NGS- and PCR-based diagnostic assays and kits will boost the industrial growth. Moreover, because of the high cancer incidence, pharmaceutical and biotechnology businesses are ensuring adequate healthcare amenities in the region.

The increasing incidence of cancer has a major role to play in the increasing demand for epigenetic processes.

Read More

How Does Cancer Drug Discovery Impact Microarray Analysis Industry?

The microarray analysis industry contributes revenue worth $3,846.7 million in 2021, and it is projected to rise at a rate of 9.9% in the coming future, to generate $9,011.1 million in revenue in 2030. 

It is ascribed to the rising application area of microarrays, growing cancer prevalence, and government initiatives for proteomic and genomic research. Microarray analysis is highly utilized in pharmaceutical screening, toxicology screening, and biomarker identification to understand DNA mutation. In addition, microarray facilitates the screening of various genes in real-time.

To learn more about this report: https://bit.ly/3lyrUH3

Moreover, North America holds a significant share of the microarray analysis industry, accounting for 40%, and it is projected to experience extensive growth in the near future, leading to increased funding from Canada and the U.S. governments for cancer research.

Under the project and category segment, consumables are expected to experience significant growth of around 10% from 2021 to 2030, led by the rising number of research institutes and diagnostic laboratories that use microarray analysis. In addition, the rising research on mRNA and DNA methylation boosts the demand for consumables to carry out microarray analyses.

In addition, software and services capture the third-largest share of the microarray analysis industry, attributed to the wide usage of the software for identifying and analyzing genomes by utilizing data for the study. Similarly, the rising number of experiments boosts the advanced services and tools adoption for carrying out studies.

DNA microarrays capture a substantial share of the industry, and it is projected to experience a growth rate of 10% in the coming years, owing to the DNA microarray's usage in clinical diagnostic tests for various diseases. Moreover, they are also utilized for determining which medicine is the best prescription for a specific patient, as these genes identify how the body manages the drug chemistry.

In addition, DNA microarrays are primarily used for mutation identification in the genetic structure. The short-single stranded DNAs of genetic disorders are produced and combined with patients' DNA for analysis. The synthetic binding of DNA with the produced DNA, and coherent material facilitates the identification of mutation type of cancer. Therefore, the growing prevalence of cancer is the primary contributor to the rising demand for DNA microarrays.

The research and academic institutes capture an extensive share of the microarray analysis industry, and they are projected to contribute to the sales worth $4.0 billion of the associate products in 2030. Over the years, there has been a significant rise in human genome study projects. Microarrays are utilized for cancer drug discovery. Therefore, the rise in research and development investments in the healthcare sector is projected to boost industry growth.

Moreover, the pharmaceutical and biotechnology companies are projected to experience rapid growth in the industry, ascribed to various research programs conducted for drug development.

In addition, Europe is the next-significant contributor after North America, attributed to the highly developed healthcare industry of the region, with advanced R&D infrastructure, and ease of access to the associated products. Cancer detection supported by point-of-care testing in Europe drives the industry growth.

Therefore, the rising investments in research and development in the healthcare sector are projected to boost industry growth. 

Read More

How Sepsis Diagnostics Help People with Infections?

A weakened immune system makes patients more susceptible to viral, bacterial, parasitic, fungal, or other infections, which can result in sepsis, a dangerous consequence. One of the most frequent causes of mortality in medical facilities is sepsis.

Additionally, the immune system responds to an infection by releasing chemicals to fight the infection, which results in sepsis. As it enters the circulation, this causes swelling throughout the body.

It deprives the body's vital organs of oxygen and nutrients and leads to poor blood flow, blood vessel leakage, blood clots, and other problems. Many medical professionals think that septic shock, which is a medical emergency, is the third stage of a three-stage disease that also has severe septic shock and sepsis.

Sepsis is more likely to affect persons with weakened immune systems, children, the elderly, and those who have cancer, AIDS, diabetes, or other chronic conditions. Thus, the global sepsis diagnostics market is expected to reach USD 1,109.0 million by 2030.

The present sepsis diagnostic techniques rely on vague physiological and clinical parameters, which frequently make it challenging to distinguish between sepsis and a systemic inflammatory response brought on by normal inflammation.

Get the sample pages of this report: https://bit.ly/3DPEBmZ

The first line of defense against blood clotting, infection, and decreased oxygen availability is the blood test. Additional laboratory examinations such as urine tests wound secretions, and respiratory secretions come next.

Moreover, computed tomography, x-rays, ultrasound, and magnetic resonance imaging (MRI) are subsequently utilized if the diagnosis of sepsis and, consequently, the cause of inflammation, cannot be made using these procedures.

The CDC focuses on five essential sepsis factors: raising awareness of sepsis through involving clinical professional organizations and patient advocates. Align infection control, chronic disease treatment, and effective antibiotic use to improve the early detection of sepsis.

The government is also promoting sepsis awareness and generating money. Resolution WHA 70.7 on Improving the Prevention, Diagnosis, and Clinical Management of Sepsis was just approved by the 17th World Health Assembly.

Novel biomarkers for the diagnosis of sepsis are being developed. It is anticipated that the demand for innovative diagnostic approaches would be driven by the increased occurrence of sepsis and infectious diseases.

According to an article in the Infection & Chemotherapy Journal, the use of biomarkers for risk assessment, treatment response monitoring, diagnosis, and outcome prediction is possible. More than 170 biomarkers, including procalcitonin, C-Reactive Protein, various cytokines, and cell surface markers, have been proven to be helpful in determining sepsis.

What Brings on Sepsis?

The most frequent cause of sepsis is bacterial infections. Infections with viruses, parasites, or fungi can also result in sepsis. Any variety of locations throughout the body can serve as the infection's source. The following are typical places and infection types that can cause sepsis:

The abdomen: An infection of bowel problems, appendicitis, peritonitis, and liver or gallbladder infections.

The skin: Bacteria can infiltrate the skin through cuts, rashes, or holes created by intravenous (IV) catheters. Sepsis can also be brought on by conditions like cellulitis, an inflammation of the connective tissues of the skin.

The urinary tract (kidneys or bladder): If the patient uses a urinary catheter to drain urine, urinary tract infections are more common.

Read More